Chief Financial Officer at Mirati Therapeutics, Inc.
Greater San Diego Area
Mirati Therapeutics, Inc.
Vice President of Finance
March 2013 to Present
Amylin Pharmaceuticals, Inc
Sr. Director, Finance
November 2011 to January 2013
Director, Corporate Financial Planning & Analysis
December 2010 to November 2011
Manager/Senior Manager/Associate Director/Director of Financial Reporting
April 2001 to December 2010
December 2000 to April 2001
Ernst & Young
August 1997 to December 2000
Mirati Therapeutics is a clinical stage pharmaceutical company focused on developing therapies that target genetic and epigenetic drivers of cancer. Mirati Therapeutics is a clinical stage pharmaceutical company focused on developing therapies that target genetic and epigenetic drivers of cancer.
What company does Jamie Donadio work for?
Jamie Donadio works for Mirati Therapeutics, Inc.
What is Jamie Donadio's role at Mirati Therapeutics, Inc.?
Jamie Donadio is Vice President of Finance
What industry does Jamie Donadio work in?
Jamie Donadio works in the Pharmaceuticals industry.
Senior finance executive with over 15 years of experience focused in the life science industry seeking a leadership role in the finance organization of a growing life sciences company. Demonstrated ability to shift quickly between the strategic and tactical, work effectively across all levels of the organization and build strategic cross-functional relationships to drive business results. Qualifications include Big Four audit experience and progressive management responsibilities in corporate accounting and finance. Specialties: Financial Modeling and Analysis Financial Planning and Forecasting Financing and Capital Formation Strategy Investor Relations Business Development SEC Reporting Technical Accounting Sarbanes-Oxley U.S. GAAP Management ReportingVice President of Finance @ Mirati Therapeutics is a clinical stage pharmaceutical company focused on developing therapies that target genetic and epigenetic drivers of cancer. From March 2013 to Present (2 years 10 months) Sr. Director, Finance @ Senior leader responsible for a wide range of corporate finance activities including the development of financial plans aligned to the Company’s strategic objectives. Specific focus on financing and capital formation strategy, treasury operations and strategic financial analysis. Key Accomplishments Include: • Recommended financial plans and forecasts to senior management and Board of Directors and improved timeliness and reliability of quarterly forecasting and annual planning process. Resulted in final plans and forecasts being available in advance of quarterly earnings calls to inform financial messaging to external stakeholders. • Selected as team member and financial advisor for various strategic transactions including reacquisition of product rights from Eli Lilly for $1.8 billion in total consideration and acquisition of Amylin by Bristol Myers Squibb for $7 billion in total consideration. Included providing strategic input on alternatives and development of the financial valuation analysis that served as framework for the evaluation of these strategic transactions. • Advised CFO and CEO on financing strategy. Included interaction with capital markets advisors to assess market opportunities and participation in execution of $211 million secondary equity offering. • Finance liaison to investor relations responsible for developing financial messaging for quarterly earnings calls and other investor communications. Included interaction with sell-side and buy-side analysts on financial matters. Financial messaging consistently resulted in driving consensus expectations to desired ranges. • Lead finance representative on product revenue forecasting and managed markets leadership teams. Provided strategic input and financial approval for product revenue forecasts and managed markets strategy. o Improved financial accountability of managed care contracting process by implementing profitability analysis of contract/no contract scenarios. From November 2011 to January 2013 (1 year 3 months) Director, Corporate Financial Planning & Analysis @ enior leader responsible for a wide range of corporate finance activities including the development of financial plans aligned to the Company’s strategic objectives. Specific focus on financing and capital formation strategy, treasury operations and strategic financial analysis. From December 2010 to November 2011 (1 year) Manager/Senior Manager/Associate Director/Director of Financial Reporting @ Leader of team of seven responsible for wide range of corporate accounting and regulatory reporting processes including SEC reporting and technical accounting analysis, Audit Committee reporting, revenue accounting, federal government price reporting, managed care contracting and rebate operations. Key accomplishments include: • Implemented Sarbanes Oxley Section 404. • Led Audit Committee compliance process. Enabled compliance within changing regulatory environment by implementing structured Audit Committee reporting and compliance processes. • Directed staff responsible for preparation of Forms 10-Q and 10-K and led document review discussions with Disclosure Committee and Audit Committee. Accelerated filing timelines in response to changes in regulatory requirements and by approximately an additional week. • Directed staff responsible for technical accounting analysis and implementation of new accounting standards. o Established critical accounting policies and processes including revenue recognition for initial product launches and accounting for two global collaboration agreements. o Led implantation of various new accounting standards including those related to accounting for stock-based compensation, and accounting for cash-settled convertible debt. • Established product revenue accounting processes and led implementation of new processes to reflect the impact of healthcare reform on reported product revenues. • Supported public and private equity and debt financing transactions generating >$2 billion in proceeds. • Directed team responsible for federal government price reporting, managed care contracting and rebate operations. Oversaw accurate and timely implementation of new Medicaid pricing regulations. • Championed implementation of commercial rebate processing system resulting in over $1 million in annual savings due to identification of invalid rebate claims. From April 2001 to December 2010 (9 years 9 months) Sr. Accountant @ Responsible for general ledger close, preparation of internal financial statements From December 2000 to April 2001 (5 months) Senior Auditor @ • Focus on public and private biotechnology, manufacturing and retail clients. • Managed audit engagements, including development of audit strategy, audit programs and preparation of audit report. • Performed audits of private and publicly held biotechnology, retail and manufacturing companies, including review of Form 10-Q and Form 10-K filings. From August 1997 to December 2000 (3 years 5 months) Jamie Donadio is skilled in: Financial Modeling, Sarbanes-Oxley Act, Mergers & Acquisitions, Forecasting, Financial Reporting, Financial Analysis, SEC filings, Auditing, Corporate Finance, Finance, Pharmaceutical Industry, Accounting, Executive Management, Valuation, Strategic Financial Planning
Extraversion (E), Sensing (S), Thinking (T), Judging (J)
3 year(s), 1 month(s)
There's 96% chance that Jamie Donadio is seeking for new opportunities
Enjoy unlimited access and discover candidates outside of LinkedIn
Trusted by 400K users from
76% of Fortune 500 companies
The most accurate data ever
Hire Anyone, Anywhere
with ContactOut today
Making remote or global hires? We can help.
No credit card required